Pathophysiology of deep vein thrombosis

Navarrete, Simón; Solar, Carla; Pizarro, Roberto; Pereira, Jaime; Fuentes, Eduardo; Palomo, Iván

doi:10.1007/s10238-022-00829-w

Cited by 40 publications

(30 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compelling evidence has highlighted the paramount hazardous characteristics of thromboembolic diseases to human health, due to their close relationship with disability and mortality worldwide. During the process of thrombosis, platelet activation and aggregation are identified as the initiating steps contributing to the development of this pathological disorder, emphasizing antiplatelet medications as the key means for minimizing the risk of these ischemic and anoxic events [135,136]. In view of the prothrombotic actions of ADP, collagen, arachidonic acid, thrombin, TXA 2 , and TXB 2 , CA was discovered to weaken platelet activation and aggregation induced by the above mentioned cytokines, which was partly attributed to the drug-evoked effects on synthesis inhibition and receptor antagonism of these bioactive substances [137][138][139][140].…”

Section: Suppression Of Platelet Activation and Aggregationmentioning

confidence: 99%

The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases

Lü

Xiong

Zhou

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Evidence from epidemiological studies has demonstrated that the incidence and mortality of cardiovascular diseases (CVDs) increase year by year, which pose a great threat on social economy and human health worldwide. Due to limited therapeutic benefits and associated adverse effects of current medications, there is an urgent need to uncover novel agents with favorable safety and efficacy. Cinnamaldehyde (CA) is a bioactive phytochemical isolated from the stem bark of Chinese herbal medicine Cinnamon and has been suggested to possess curative roles against the development of CVDs. This integrated review intends to summarize the physicochemical and pharmacokinetic features of CA and discuss the recent advances in underlying mechanisms and potential targets responsible for anti-CVD properties of CA. The CA-related cardiovascular protective mechanisms could be attributed to the inhibition of inflammation and oxidative stress, improvement of lipid and glucose metabolism, regulation of cell proliferation and apoptosis, suppression of cardiac fibrosis, and platelet aggregation and promotion of vasodilation and angiogenesis. Furthermore, CA is likely to inhibit CVD progression via affecting other possible processes including autophagy and ER stress regulation, gut microbiota and immune homeostasis, ion metabolism, ncRNA expression, and TRPA1 activation. Collectively, experiments reported previously highlight the therapeutic effects of CA and clinical trials are advocated to offer scientific basis for the compound future applied in clinical practice for CVD prophylaxis and treatment.

show abstract

Section: Suppression Of Platelet Activation and Aggregationmentioning

confidence: 99%

The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases

Lü

Xiong

Zhou

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Rivaroxaban is a selective Xa factor inhibitor while dabigatran is a direct thrombin inhibitor. 3,6 This means that dabigatran blocks coagulation at a later stage in the cascade of thrombus formation, probably making it more potent against some thrombophilias. The REMEDY and RECOVER trials have shown that the efficacy and safety of dabigatran were not significantly affected by the presence of thrombophilia.…”

Section: Discussionmentioning

confidence: 99%

“…1 It can be caused by several acquired factors such as trauma, immobilization, cancer, inflammatory disease, and others, although most events are unprovoked. 2,3 In some unprovoked cases, the underlying factor is some type of hereditary thrombophilia (HT), which is a genetic propensity to develop venous or arterial thromboembolism, and it includes gene mutations of different coagulation factors such as protein C or S, V Leiden, antithrombin, and prothrombin G20210A. 4 Although V Leiden and prothrombin mutations are the most commonly detected, antithrombin and protein C/S mutations are associated with the highest risk for VTE and pulmonary embolism.…”

Section: Introductionmentioning

confidence: 99%

Direct oral anticoagulants for deep vein thrombosis among patients with hereditary thrombophilia—A cohort study

Galyfos,

Chamzin,

Charalampopoulos

et al. 2023

Phlebology

View full text Add to dashboard Cite

Objectives to evaluate direct oral anticoagulants (DOACs) in patients with hereditary thrombophilia and deep venous thrombosis (DVT). Methods This is a retrospective observational study. Results In total, 45 patients were treated between 01/2012 and 12/2022 (mean follow-up: 1.5 +/− 0.3 years). The most frequent thrombophilias were heterozygous V Leiden (20%), heterozygous MTHFR C677T (37.8%), heterozygous MTHFR A1298C (24.4%), and hyperhomocysteinemia (26.7%). The patients received rivaroxaban ( n = 19), apixaban ( n = 15), and dabigatran ( n = 11). Three cases presented symptoms’ recurrence without evidence of thrombosis’ recurrence (two under rivaroxaban and one under apixaban; p > .05). These patients improved under parenteral anticoagulation and were further treated with dabigatran. No other event or major bleeding occurred during the follow-up. The presence of more than two factors was associated with acute recurrence of symptoms (OR = 25.9; 95% CI [1.454–461.262]; p = .026). Conclusions DOACs seem to be safe and efficient for patients with hereditary thrombophilia and DVT. The presence of more than two thrombophilia factors is associated with a higher risk for symptom recurrence. Although statistically non-significant, symptoms’ recurrence was also observed more frequently among patients under anti-Xa inhibitors than antithrombin inhibitors. This should be verified in larger comparative studies.

show abstract

“…Частота симптоматичного тромбозу глибоких вен (ТГВ), який виявляється вперше, коливається від 50 до 100 на 100 000 населення в рік, при цьому, якщо врахувати тромбоемболію легеневої артерії (ТЕЛА), то загальна захворюваність приблизно на 25% вища [5,26]. Частіше ТГВ зустрічається у жінок у віці від 20 до 45 років, тоді як у чоловіків відповідно у віці від 45 до 60 років [5,17]. ТЕЛА є причиною до 300 000 смертей на рік у США, та є однією з основних причин смертності від серцевосудинних захворювань [1,25].…”

Section: вступunclassified

Features of treatment of venous thromboembolism in patients with abnormalities in the development of the vena cava inferior

Khrebtiy¹

2023

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. In the treatment of venous thromboembolism, a special place is occupied by patients with congenital anomalies of the development of the inferior vena cava (IVC). To date, only single cases of treatment of this pathology have been described in the literature. Studying the experience of treating patients with congenital anomalies of the IVC will allow to improve the results of treatment of this category of patients. We analyzed the results of treatment of 1243 patients with venous thromboembolism from 2010 to 2022. For the diagnosis of venous thromboembolism, we used duplex scanning of the veins of the lower extremities, phlebography by spiral computed tomography (SCT), angiopulmonography, and phlebography. 32 (2.5%) patients had bilateral thrombosis of the ileofemoral venous segment. Congenital anomalies of IVC development were diagnosed in 2 (0.16%) patients. One patient had IVC aplasia, the other had IVC hypoplasia. Both patients had bilateral ileofemoral phlebothrombosis. For the treatment of patients with congenital anomalies of IVC and bilateral ileofemoral deep vein thrombosis, we used anticoagulant therapy and elastic compression of the lower extremities. During the study period, venous thromboembolic complications in the form of pulmonary embolism were not recorded, fatal complications were not diagnosed. Massive bleeding was not diagnosed in this category of patients during the study period. Thus, the conducted analysis allows us to state that the use of anticoagulant therapy allows to obtain satisfactory results of treatment of patients with congenital abnormalities of the development of the IVC.

show abstract

Pathophysiology of deep vein thrombosis

Cited by 40 publications

References 125 publications

The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases

The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases

Direct oral anticoagulants for deep vein thrombosis among patients with hereditary thrombophilia—A cohort study

Features of treatment of venous thromboembolism in patients with abnormalities in the development of the vena cava inferior

Contact Info

Product

Resources

About